Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, OH; PGY-1 Internal Medicine, Cleveland Clinic Akron General, Akron, OH.
Department of Hematology and Medical Oncology, Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland Clinic, Cleveland, OH; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
Cleve Clin J Med. 2024 Feb 2;91(2):109-117. doi: 10.3949/ccjm.91a.23017.
Venous thromboembolism (VTE) is a major health burden in patients with cancer, causing morbidity, emergency room visits, hospitalizations, and death. Treatment is challenging, as it is necessary to balance the risk of recurrent thrombosis and bleeding associated with anticoagulants. Treatment paradigms are shifting from low-molecular-weight heparin monotherapy. Multiple recent randomized controlled trials have demonstrated the safety and efficacy of direct oral anticoagulants in this setting. Current studies are evaluating factor XI inhibitors as potential treatments for cancer-associated VTE.
静脉血栓栓塞症（VTE）是癌症患者的主要健康负担，导致发病率、急诊就诊、住院和死亡。治疗具有挑战性，因为必须平衡抗凝剂相关的复发性血栓形成和出血风险。治疗模式正在从低分子量肝素单一疗法转变。最近多项随机对照试验证明了直接口服抗凝剂在这种情况下的安全性和有效性。目前的研究正在评估因子 XI 抑制剂作为癌症相关 VTE 的潜在治疗方法。
